Toripalimab Biosimilar (PDCD1 / PD-1 / CD279 Reference Antibody)
Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma.
Product Specifications
Target
Toripalimab Biosimilar (Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Clonality
Monoclonal
Conjugation
Unconjugated
Field of Research
Cancer Biology; Immunology & Inflammation; Cell Biology
Purity
>98%
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
PE-Linked Polyclonal Antibody to Brain Natriuretic Peptide (BNP)